Obinutuzumab plus chemotherapy FDA approved for follicular lymphoma

Non-Sponsored Content

By: scienterrific | Last updated: 16 November 2017 | In: US FDA Onc\Haem Approvals, Uncategorised

Article Keywords

lymphoma, Roche, obinutuzumab, FDA, Genentech, Gazyva

On 16 November 2017, the FDA granted regular approval to obinutuzumab (Gazyva®, Genentech) in combination with chemotherapy, followed by obinutuzumab monotherapy in adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL) patients who achieved at least a partial remission.

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content